Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
Meshkat S, Teopiz K, Di Vincenzo J, Bailey J, Rosenblat J, Ho R, Rhee T, Ceban F, Kwan A, Cao B, McIntyre R. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder. Journal Of Affective Disorders 2023, 340: 893-898. PMID: 37557991, DOI: 10.1016/j.jad.2023.08.027.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntidepressant effectsGamma-aminobutyric acidDepressive disorderAdverse eventsTreatment-emergent adverse eventsFuture research vistasSerious adverse eventsGABAA receptor expressionEtiology of MDDExtrasynaptic GABAA receptorsCommon mental disordersPositive allosteric modulatorsNeuroactive steroidsClinical efficacyTreatment courseInhibitory GABAergicClinical trialsPostpartum depressionZuranoloneGABAA receptorsReceptor expressionTreatment approachesMental disordersAllosteric modulators
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply